Macrolide antibiotic roxitromycin - the main clinical and pharmacological aspects of application


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Roxithromycin is a classic representative of 14-membered macrolides and has a number of clinically significant therapeutic features. Pharmacodynamic and pharmacokinetic properties of roxithromycin in combination with high safety have been confirmed in numerous clinical studies. The high efficacy of the antibiotic, regardless of the frequency of its administration, makes it possible to widely use roxithromycin in the treatment of infections in both adults and children.

Full Text

Restricted Access

About the authors

Ola A. Egorova

Smolensk State Medical University; Smolensk Regional Clinical Hospital

Email: Ola-egorova@yandex.ru
PhD, Teaching Assistant at the Department of Otorhinolaryngology; Head of the Children’s Otorhinolaryngological Department

References

  1. Матвеев А.В., Крашенинников А.Е., Егорова Е.А. Вопросы безопасности эритромицина. Клиническая микробиология и антимикробная химиотерапия. 2018;20(3):199-204.
  2. Веселов А.В. Клинико-фармакологические аспекты практического применения рок-ситромицина. Фарматека. 2006;4:28-37.
  3. Шиленкова В.В. Пять причин назначить макролиды при заболеваниях ЛОР-органов. Медицинский совет. 2016;9:40-4.
  4. Mandell G.L., Douglas R.G., Bennett J.E., et al. Anti-infective therapy. New York; Edinburgh, London, Melbourne. 1985. P. 197-218.
  5. Заплатников А.П. Макролидные антибиотики при лечении инфекций органов дыхания у детей. Лечебное дело. 2002;1:32-7.
  6. Амиров Н.Б., Визель А.А. Макролиды в лечении различных бактериальных инфекций. Вестник современной клинической медицины. 2012;5(4):43.
  7. Bryskier A., Bergogne-Berezin E. Macrolides. In: Antibacterial and antifungal Agents. A. Bryskier, ed. ASM-Press (Washington DC). 2005.
  8. Omura S., ed. Macrolide Antibiotics. 2nd edition. Academic Press, 2002.
  9. Phillips I., Pechere J-C., Davies A., et al. Roxithromycin: a new macrolides. Symposium. Paris, 29-30 may 1987. J. Antimicrob Chemopther 1987;20:1-187.
  10. Bergan T. Pharmacokinetics of newer macrolides. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. H.C. Neu, L.S. Young, S.H. Zinner, J.F. Acar (Eds.). N.-Y, etc., 1995. Р. 51-60.
  11. Bergogne-Berezin E. Clinical significance of studies on antibiotic concentrations in the lower respiratory tract. In: Predicting Antibiotic Response in Respiratory Tract Infections. Highlights from the 7th International Congress for Infectious Diseases. Hong Kong, 1996. Р. 7-8.
  12. Begue P., Kafetzis D.A., Albin H., et al. Pharmacokinetics of roxithromycin in paediatrics. J. Antimicrob. Chemother. 1987;20(B):1016.
  13. Masaki M., Inoue Y., Mashimoto H., et al. Laboratory and clinical studies on RU 28965. Chemother. 1988;36(4):421-37.
  14. Hoffler D., Koeppe P, Sorgel F., et al. The pharmacokinetics of roxithromycin in dialysis patient. In: The 18th International Congress of Chemotherapy. Stockholm. 1993;abstr. 260.
  15. Felmingham D., Feldman C., Hryniewicz W., et al. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clin Microbiol Infect. 2002;8(2):12-42.
  16. Samra Z., Rosenberg S., Kaufman L. Antibiotic susceptibility of Ureaplasma urealyticum. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice. 1994; abstr. 146.
  17. Samra Z., Rosenberg S., Soffer Y., et al. In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. Diagn Microbiol Infect Dis. 2001;39:177-79.
  18. Goldstein E., Citron D., Vreni Merrinam C., et al. Activities of Telithromycin (HMR 3647, RU 66647) compares to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antibacterial agents against unusual anaerobes. Antimicrob Agents Chemother. 1999; 43:24318005.
  19. Справочник по антимикробной терапии. Выпуск 2. Под ред. Р.С. Козлова, А.В. Дехнича. Смоленск, 2010. 416 с.
  20. Решедько Г.К., Козлов Р.С. Состояние резистентности к антиинфекционным препаратам в России. В. кн.: Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. Практическое руководство по анти-инфекционной химиотерапии. Смоленск, 2007. С. 32-46.
  21. Резолюция Экспертного совета «Принципы рациональной антибиотикотерапии респираторных инфекций у детей. Сохраним антибиотики для будущих поколений» 31 марта 2018 г., Педиатрия. (Прил.) 2018;03:10-5.
  22. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2010. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm6 2011.
  23. Nagino K., Kobayashi H. Influence of macrolides on mucoid alginate biosynthetic enzyme from. Clin Microbiol Infect. 1997;3:432-39.
  24. Craig W.A., Gudmundson S. Postantibiotic effect. In: Antibiotics in Laboratory Medicine. V. Lorian (Ed.). Baltimore etc. 1996. P. 403-31.
  25. Fuursted K., Knudsen J.D., Petersen M.B., et al. Comparative study of bactericidal activities, postantibiotic effects and effects on bacterial virulence of penicillin G. and six macrolides against Streptococcus pneumoniae. Antimicrob Agents Chemother. 1997;41:781-84.
  26. Odenholt-Tornqvist I., Lowdin E., Cars 0. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. Antimicrob Agents Chemother. 1995;39:221-26.
  27. Tateda K., Ishii Y., Matsumoto T., et al. Direct evidence for antipseudomonal activity of macrolides; exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother 1996; 40:2272271.
  28. Андреева И.В., Стецюк О.У., Азовскова О.В., Козлов Р. С. Терапия острого тонзиллофаринги-та: современные рекомендации и российские особенности. Клиническая микробиология и антимикробная химиотерапия. 2013;15(3): 198-211.
  29. Pichichero M.E., Casey J.R. Systematic review of factors contributing to penicillin treatment failure in Streptococcus pyogenes pharyngitis. Otolaryngol Head NeckSurg. 2007;137(6):851-57.
  30. Kaplan E.L., Johnson D.R. Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G. and of oral penicillin V. in eradication of group a streptococci from children with acute pharyngitis. Pediatr. 2001;8:1180-86.
  31. Kaplan E.L., Chhatwal G.S., Rohde M. Reduced ability of penicillin to eradicate ingested group A streptococci from epithelial cells: Clinical and pathogenetic implications. Clin Infect Dis. 2006;43(11):1398-406.
  32. Carbon C., Hotton J.M., Pepin L.F., et al. Economic analysis of antibiotic regimens used in the treatment pharyngitis: a prospective comparison of azithromycin versus roxithromycin. J. Antimicrob Chemother. 1996;37(C):151-61.
  33. Mira E., Benazzo M. A multicenter study on the clinical efficacy and safety of roxithromycin in the treatment of ear-nose-throat infections: comparison with amoxycillin/clavulanic acid. J. Chemother. 2001;13:621-27.
  34. Bazet M.C., Blanc F., Chumdermpadetsuk S., et al. Roxithromycin in the treatment of paediatric infections. Br J. Clin Pract. 1988;42(55):117-18.
  35. Гаращенко Т.И. Макролиды в терапии острого тонзиллита и его осложнений у детей. РМЖ. 2001;9( 19):812-16.
  36. Thamlikitkul V., Kobwanthanakun S., Pruksachatvuthi S., et al. Pharmacokinetics of rheumatic fever prophylaxis regimens. J. Int Med Res. 1992;20:20-6.
  37. Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. Практическое руководство по антиинфек-ционной химиотерапии. Смоленск, 2007.
  38. Karalus N.C., Garrett J.E., Lang S., et al. Roxithromycin 150 mg b.i.d. versus amoxicillin 500 mg/ clavulanic acid 125 mg t.i.d. for the treatment of lower respiratory tract infections in general practice. Infection. 1995;23:15-20.
  39. Marsac J.H. An international clinical trial on the efficacy and safety of roxithromycin in 40,000 patients with acute community-acquired respiratory tract infections. Diagn Microbiol Infect Dis. 1992;15(4):81-4.
  40. de Campora E., Camaioni A., Leonardi M., et al. Comparative efficacy and safety of roxithromycin and clarithromycin in upper respiratory tract infections. Diagn Microbiol Infect Dis. 1992;15(4):119-22.
  41. Laurencena E., Forti M.J. Roxithromycin in the treatment of acute otitis media in children. Prensa Med Argent. 1992;79:577-79.
  42. Casellas J.M., Rodriguez H.A., Fernandez-Macloughlin G.J., et al. Efficacy of roxithromycin in the treatment of acute otitis media in infants. Br J. Clin Pract. 1988;42(55):113-14.
  43. Stamboulian D., Perianu M. The efficacy of roxithromycin (300 mg once daily or 150 mg BID) in the treatment of "atypical" pneumonia in an international multicentre study In: The 17th International Congress of Chemotherapy. Berlin, 1991.
  44. Salvarezza C., Villar E., Ballario M. Estudio comparative de la eficacia y tolerancia clinica de roxitromicina vs. amoxicillina en neumopatia extrahospitalarias en pediatria. Prensa Med Argent. 1989;76:127-30.
  45. Блохин Б.М., Стешин В.Ю. Эспарокси в мабу-латорной практике педиатра. Практическая пульмонология. 2015;3:96-9.
  46. Свистушкин В.М., Гринев И.А., Стецюк О.У, Андреева И.В Рекомендации по ведению взрослых пациентов с острым риносинуси-том: достижим ли консенсус? Лечащий врач. 2012;11:90
  47. Свистушкин В.М., Андреева И.В., Стецюк О.У. Обзор современных рекомендаций по тактике ведения пациентов с острым бактериальным риносинуситом в педиатрической практике. Клиническая микробиология и антимикробная химиотерапия. 2012;14(3):176-90.
  48. Chatzimanolis E., Marsan N., Lefatzis D., et al. Comparison of roxithromycin with co-amoxiclav in patients with sinusitis. J. Antimicrob Chemother. 1998;41(B):81-4.
  49. Ерохин А.И., Гостев М.С. Противомикробный препарат Эспарокси и его применение в стоматологической практике. Клиническая практика. 2010. С. 15.
  50. Deffez J.P., Sheimberg A., Rezvani Y. Milticenter double-blind study of the efficacy and tolerance of roxithromycin versus erythromycin ethylsuccinate in acute orodental infection in adults. Diagn Microbiol Infect. Dis. 1992;15:133-37.
  51. De Vlieger A., Druart M., Puttemans M. Roxithromycin versus doxycycline in the treatment of acute exacerbations of chronic bronchitis. Diagn Microbiol Infect Dis. 1992;15(4):123-27.
  52. Antela A., Guerrero A., Escudero R., et al. Efficacy and safety of roxithromycin as empiric therapy for lower respiratory tract infections. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice. 1994;abstr. 278.
  53. Portier H., Brambilla C., Garre M., et al. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. Eur J. Clin Microbiol Infect Dis. 2005;24:367-76.
  54. Bernard P., Plantin P., Roger H., et al. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br J. Dermatol. 1992;192:157-555
  55. Akamatsu H., Nishijima S., Akamatsu M., et al. Clinical evaluation of roxithromycin in patients with acne. J. Int Med Res. 1996;24:109-14.
  56. Derevianko I. Efficacy of roxithromycin in urogenital infection due to chlamydia trachomatis. 3rd International Conference on Macrolides, Azalides andStreptogramis, Lisbon, Portugal, 1996. 27p.
  57. Bircher A.J., Gelzer D., Rufli T. Roxithromycin in the treatment of non-gonococcal urethritis. A double blind comparison of two treatment regimens. In: The 16th Congress of Chemotherapy. Jerusalem. 1989;abstr. 226.
  58. Takizawa H., Ohtoshi T., Takeuchi N., et al. Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrob. Agents Chemother. 1998;42:1499-502.
  59. Amsden G.W. Anti-inflammatory effects of macrolides an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? Antimicrob Chemother. 2005; 55:10521.
  60. Жаркова Л.П. Место рокситромицина в лечении инфекций дыхательных путей. Фарматека. 50;3;4:50-6.
  61. Бакумова О.Р., Шахова Е.Г. Роль макроли-дов в патологии ЛОР-органов. Фарматека. 50;4;;0:9;-0.
  62. Мубаракшина О.А., Дронова Ю.М. Современные подходы к лечению микоплазменных инфекций дыхательных путей. Фарматека. 2015;14:28-33.
  63. Witt A., Sommer E.M., Cichna M., et al. Placental passage of clarithromycin surpasses other macrolide antibiotics. Am J. Obstet Gynecol. 2003;188:816-19.
  64. Czeizel A.E., Rockenbauer M., Olsen J., et al. A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta Obstet Gynecol. Scand. 2000;79:234-37.
  65. Pechere J.-C. Clinical evaluation of roxithromycin 300 mg once daily as an alternative to 150 mg twice daily. Diagn Microbiol Infect Dis. 1992;15(4):111-17.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies